TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use
Clinical trial NCT00225303 · COMPLETED
Trial details
- NCT number
- NCT00225303
- Sponsor
- Tibotec Pharmaceuticals, Ireland
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2005-03-01
- Enrollment
- 116
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.